menu

Unresectable HCC: An Emerging Era of Combination Therapy – A Clinical Convergence®

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Unresectable HCC: An Emerging Era of Combination Therapy – A Clinical Convergence®

close
0.75 credits
45 minutes
Unresectable HCC: An Emerging Era of Combination Therapy – A Clinical Convergence®
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.75 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    In this web-based CME activity, experts discuss recent developments in the treatment of hepatocellular carcinoma (HCC). Do not miss this opportunity to learn more about new and emerging combination strategies and receive practical guidance on their integration into clinical practice.  

    You will hear first-hand from an experienced patient with HCC who will share his personal journey and offer a novel perspective for healthcare professionals.

  • Faculty Credentials

    Richard S. Finn, MD
    Professor, Department of Medicine​
    Division of Hematology/Oncology​
    UCLA David Geffen School of Medicine ​
    Director, Signal Transduction and Therapeutics Program​
    Jonsson Comprehensive Cancer Center ​
    University of California ​
    Los Angeles, CA

    Amit Singal, MD, MS   
    David Bruton Jr. Professor, Clinical Cancer Research  
    Professor, Medicine  
    Chief and Medical Director, Liver Tumor Program  
    UT Southwestern Medical Center  
    Dallas, TX 

    Mark Yarchoan, MD 
    Assistant Professor, Division of GI Malignancies 
    Medical Oncology Director, Liver Cancer Multidisciplinary Clinic 
    Sidney Kimmel Comprehensive Cancer Center 
    Johns Hopkins
    Baltimore, MD 

  • Target Audience

    This activity is intended for hepatology, hematology/oncology, and other clinicians including physicians, NPs, and PAs who diagnose and manage patients with hepatocellular carcinoma (HCC).

  • Learning Objectives

    After engaging in this activity, clinicians will be able to:

    • Develop treatment plans for patients with advanced hepatocellular carcinoma (HCC) that integrate checkpoint inhibitors and targeted synthetic agents based on their efficacy and safety data 
    • Develop individualized treatment plans for patients with advanced HCC across multiple lines of therapy 
    • Analyze the safety and efficacy of new and emerging combination regimens for HCC 
  • Accreditation and Credit Designation Statements

    Physicians
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians. 

    AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Physician Assistants 
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

  • Commercial Support

    This educational activity is supported by medical education grants from Eisai Inc., Exelixis, Inc., Genentech, a member of the Roche Group, and Merck & Co., Inc.

  • Disclosure of Conflicts of Interest

    It is the policy of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH and RMEI prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.

  • Disclosure Declarations

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

    Richard S. Finn, MD, has affiliations with:
    AstraZeneca, Bayer, BMS, Cstone, Eisai, Eli Lilly, Merck, Pfizer, Roche/Genentech (Consultant); BMS, Eli Lilly, Eisai, Merck, Pfizer, Roche/Genentech (Contracted Research - Paid to UCLA).
    Amit Singal, MD, MS, has affiliations with:
    AstraZeneca, Bayer, BMS, Eisai, Exelixis, Genentech (Consultant).
    Mark Yarchoan, MD, has affiliations with:
    AstraZeneca, Eisai, Exelixis (Advisory Board).

    Patient Panelist
    William Beesting, PhD, has no financial relationships to disclose.

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

    AKH Staff and Planners
    Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner, has no financial relationships to disclose.
    Patricia Brignoni, AKH Director of Operations, has no financial relationships to disclose.

    RMEI Medical Education, LLC
    Yael Waknine, Medical Director, has no financial relationships to disclose.
    Sharon Powell has no financial relationships to disclose.
    Elizabeth Johnson has no financial relationships to disclose

  • Disclosure of Unlabeled Use

    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

  • How to Receive Your Credit

    Statements of credit will be awarded based on the participant reviewing the presentation, scoring 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com.

  • Your Feedback is Important to Us

    COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
    INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

    *The expense for this gift card is solely funded by RMEI Medical Education, LLC. No supporter funding was used for the expense of this gift card.

    Rules and Regulations 
    This sweepstake is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. 

  • Media

    Internet

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    In this web-based CME activity, experts discuss recent developments in the treatment of hepatocellular carcinoma (HCC). Do not miss this opportunity to learn more about new and emerging combination strategies and receive practical guidance on their integration into clinical practice.  

    You will hear first-hand from an experienced patient with HCC who will share his personal journey and offer a novel perspective for healthcare professionals.

  • Faculty Credentials

    Richard S. Finn, MD
    Professor, Department of Medicine​
    Division of Hematology/Oncology​
    UCLA David Geffen School of Medicine ​
    Director, Signal Transduction and Therapeutics Program​
    Jonsson Comprehensive Cancer Center ​
    University of California ​
    Los Angeles, CA

    Amit Singal, MD, MS   
    David Bruton Jr. Professor, Clinical Cancer Research  
    Professor, Medicine  
    Chief and Medical Director, Liver Tumor Program  
    UT Southwestern Medical Center  
    Dallas, TX 

    Mark Yarchoan, MD 
    Assistant Professor, Division of GI Malignancies 
    Medical Oncology Director, Liver Cancer Multidisciplinary Clinic 
    Sidney Kimmel Comprehensive Cancer Center 
    Johns Hopkins
    Baltimore, MD 

  • Target Audience

    This activity is intended for hepatology, hematology/oncology, and other clinicians including physicians, NPs, and PAs who diagnose and manage patients with hepatocellular carcinoma (HCC).

  • Learning Objectives

    After engaging in this activity, clinicians will be able to:

    • Develop treatment plans for patients with advanced hepatocellular carcinoma (HCC) that integrate checkpoint inhibitors and targeted synthetic agents based on their efficacy and safety data 
    • Develop individualized treatment plans for patients with advanced HCC across multiple lines of therapy 
    • Analyze the safety and efficacy of new and emerging combination regimens for HCC 
  • Accreditation and Credit Designation Statements

    Physicians
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians. 

    AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Physician Assistants 
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

  • Commercial Support

    This educational activity is supported by medical education grants from Eisai Inc., Exelixis, Inc., Genentech, a member of the Roche Group, and Merck & Co., Inc.

  • Disclosure of Conflicts of Interest

    It is the policy of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH and RMEI prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.

  • Disclosure Declarations

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

    Richard S. Finn, MD, has affiliations with:
    AstraZeneca, Bayer, BMS, Cstone, Eisai, Eli Lilly, Merck, Pfizer, Roche/Genentech (Consultant); BMS, Eli Lilly, Eisai, Merck, Pfizer, Roche/Genentech (Contracted Research - Paid to UCLA).
    Amit Singal, MD, MS, has affiliations with:
    AstraZeneca, Bayer, BMS, Eisai, Exelixis, Genentech (Consultant).
    Mark Yarchoan, MD, has affiliations with:
    AstraZeneca, Eisai, Exelixis (Advisory Board).

    Patient Panelist
    William Beesting, PhD, has no financial relationships to disclose.

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

    AKH Staff and Planners
    Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner, has no financial relationships to disclose.
    Patricia Brignoni, AKH Director of Operations, has no financial relationships to disclose.

    RMEI Medical Education, LLC
    Yael Waknine, Medical Director, has no financial relationships to disclose.
    Sharon Powell has no financial relationships to disclose.
    Elizabeth Johnson has no financial relationships to disclose

  • Disclosure of Unlabeled Use

    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

  • How to Receive Your Credit

    Statements of credit will be awarded based on the participant reviewing the presentation, scoring 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com.

  • Your Feedback is Important to Us

    COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
    INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

    *The expense for this gift card is solely funded by RMEI Medical Education, LLC. No supporter funding was used for the expense of this gift card.

    Rules and Regulations 
    This sweepstake is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. 

  • Media

    Internet

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 7/27/21